Xin Lang Cai Jing·2025-12-21 09:50Core Viewpoint - Company focuses on enhancing its core businesses in agricultural protection and pharmaceutical CDMO through overseas base expansion and R&D innovation, while steadily advancing its new energy business for long-term development [2] Group 1: Investor Relations Activity - On December 19, the company held an investor relations activity with five institutions, including Guohai Securities and Nomura Asset Management, discussing key issues such as agricultural protection business layout, pharmaceutical CDMO development, R&D innovation direction, and capital operation plans [1] - The meeting was attended by the company's Senior Vice President and Secretary of the Board, Chen Feibiao, and Securities Affairs Representative Dai Yiyi [1] Group 2: Agricultural Protection Business - The company plans to enhance its overseas base layout, establishing Malaysia as a second overseas base for a differentiated supply chain, collaborating with production bases in China and the UK [1] - The agricultural protection industry is highly concentrated, and the company has formed long-term strategic partnerships with several international agrochemical companies, covering all stages of the product lifecycle [1] Group 3: Pharmaceutical Business - The pharmaceutical business is expanding its coverage and deepening cooperation, focusing on products under patent protection [1] - The company aims for steady long-term growth by enhancing technical capabilities to strengthen customer cooperation [1] Group 4: R&D Innovation - The company is expanding into emerging fields such as peptide and radioactive drugs, while continuing to develop small molecule CDMO and starting materials [1] - The team has experience in delivering peptide and PEG linker products, optimizing synthesis routes based on customer needs [1] Group 5: CDMO Core Competitiveness - The company's core competitiveness lies in strong technological innovation, high safety and environmental standards, efficient production management, and a strict quality assurance system [1] - These advantages have earned recognition from leading global agricultural and pharmaceutical companies, ensuring stable and long-term cooperation [1] Group 6: Capital Operation - Currently, the company has no plans for secondary market financing, focusing capital expenditures on the construction of coastal and Malaysian bases [1] - As of the first three quarters of 2025, the company reported a net cash flow from operating activities of approximately 900 million yuan, sufficient to support planned capital expenditures [1] Group 7: New Energy Business - The company primarily sells LiFSI and electrolyte products, while improving the technology for lithium hexafluorophosphate [1] - It is expected that the new energy business will achieve significant revenue breakthroughs in 2025, leveraging its R&D and production advantages in fine chemicals [1]